Safety, Pharmacokinetics, Immunogenicity, and Clinical Response to Multiple Subcutaneous Administrations of the Human Monoclonal Antibody to Human TNF-alpha (CNTO 148) in Patients with Intermediate Uveitis, Poster Uveitis, or Panuveitis
C. Michael Samson, M.D.
To evaluate the safety of multiple subcutaneous (SC) administrations of CNTO 148 at 3 dose levels compared with placebo in subjects with intermediate uveitis, posterior uveitis, or panuveitis. This is a Phase I/IIA, double-masked, placebo-controlled, multicenter study.
Patients with intermediate uveitis, posterior uveitis, or panuveitis and disease control dependent upon a minimum dose of 0.13 mg/kg/day or 10 mg/day of systemic prednisone or equivalent, whichever is less. Patients with vitreous haze no greater than 1+ will be considered.
Study results are currently being analyzed. Please visit this webpage next month for the study update.
For more information: